By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has approved SHR-8068 injection for two clinical trials. The trials will evaluate SHR-8068 in combination with aumolertinib for advanced non-small cell lung cancer (NSCLC) and with anti-tumor drugs (adebrelimab, bevacizumab, or apatinib) for colorectal cancer.
Clinical Trial Indications
The NMPA approval includes two indications:
- Treatment of advanced NSCLC in combination with aumolertinib.
- Treatment of colorectal cancer in combination with adebrelimab, bevacizumab, or apatinib.
SHR-8068: CTLA-4 Monoclonal Antibody
SHR-8068 is an in-licensed CTLA-4 monoclonal antibody (mAb). Currently, there are two similar products on the global market: Yervoy (ipilimumab) and Imjudo (tremelimumab). This approval marks a significant step in the development of SHR-8068, positioning it as a potential new treatment option for patients with these conditions.-Fineline Info & Tech